Effects of Heparin and Bivalirudin on Thrombin-Induced Platelet Activation: Differential Modulation of PAR Signaling Drives Divergent Prothrombotic Responses

Mikael Lund; Ankit S Macwan; Kjersti Tunströmer; Tomas L Lindahl; Niklas Boknäs

doi:10.3389/fcvm.2021.717835

Effects of Heparin and Bivalirudin on Thrombin-Induced Platelet Activation: Differential Modulation of PAR Signaling Drives Divergent Prothrombotic Responses

Front Cardiovasc Med. 2021 Sep 29:8:717835. doi: 10.3389/fcvm.2021.717835. eCollection 2021.

Authors

Mikael Lund¹, Ankit S Macwan¹, Kjersti Tunströmer¹, Tomas L Lindahl^{1

2}, Niklas Boknäs^{1

3}

Affiliations

¹ Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
² Department of Clinical Chemistry and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
³ Department of Hematology and Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.

Abstract

Heparin and bivalirudin are widely used as anticoagulants in the setting of acute thrombosis. In this study, we investigated how these drugs affect the ability of thrombin to generate a prothrombotic platelet response via activation of the protease-activated receptors (PARs) 1 and 4. We examined the effects of heparin/antithrombin and bivalirudin on PAR1- and PAR4-mediated intracellular calcium mobilization, aggregation, α-granule release, and procoagulant membrane exposure in platelets exposed to thrombin concentrations likely to be encountered in the thrombus microenvironment during thrombosis. At physiological antithrombin levels, heparin treatment resulted in complete and sustained inhibition of thrombin-induced PAR4-mediated platelet activation, but transient PAR1 signaling was sufficient to elicit significant α-granule release and platelet aggregation. In contrast, bivalirudin treatment resulted in rapid and profound inhibition of signaling from both PAR receptors, followed by a delayed phase of PAR4-mediated platelet activation, resulting in a robust prothrombotic response. Combination treatment with bivalirudin and subtherapeutic concentrations of heparin completely inhibited the residual platelet activation observed with single drug treatment at all time-points. Our results show that heparin and bivalirudin have different and complementary inhibitory effects on the activation of PAR1 and PAR4 by thrombin.

Keywords: PAR1; PAR4; bivalirudin; heparin; thrombin.